JP2022506062A5 - - Google Patents

Info

Publication number
JP2022506062A5
JP2022506062A5 JP2021523218A JP2021523218A JP2022506062A5 JP 2022506062 A5 JP2022506062 A5 JP 2022506062A5 JP 2021523218 A JP2021523218 A JP 2021523218A JP 2021523218 A JP2021523218 A JP 2021523218A JP 2022506062 A5 JP2022506062 A5 JP 2022506062A5
Authority
JP
Japan
Prior art keywords
solid formulation
formulation according
solid
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523218A
Other languages
English (en)
Japanese (ja)
Other versions
JP7425794B2 (ja
JP2022506062A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057725 external-priority patent/WO2020092100A1/en
Publication of JP2022506062A publication Critical patent/JP2022506062A/ja
Publication of JP2022506062A5 publication Critical patent/JP2022506062A5/ja
Application granted granted Critical
Publication of JP7425794B2 publication Critical patent/JP7425794B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523218A 2018-10-30 2019-10-23 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用 Active JP7425794B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752685P 2018-10-30 2018-10-30
US62/752,685 2018-10-30
PCT/US2019/057725 WO2020092100A1 (en) 2018-10-30 2019-10-23 Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof

Publications (3)

Publication Number Publication Date
JP2022506062A JP2022506062A (ja) 2022-01-17
JP2022506062A5 true JP2022506062A5 (cg-RX-API-DMAC7.html) 2022-10-20
JP7425794B2 JP7425794B2 (ja) 2024-01-31

Family

ID=70464349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523218A Active JP7425794B2 (ja) 2018-10-30 2019-10-23 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用

Country Status (9)

Country Link
US (2) US12358870B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873443A4 (cg-RX-API-DMAC7.html)
JP (1) JP7425794B2 (cg-RX-API-DMAC7.html)
KR (1) KR102991240B1 (cg-RX-API-DMAC7.html)
CN (1) CN112955130A (cg-RX-API-DMAC7.html)
MX (1) MX418110B (cg-RX-API-DMAC7.html)
MY (1) MY209101A (cg-RX-API-DMAC7.html)
SG (1) SG11202104208RA (cg-RX-API-DMAC7.html)
WO (1) WO2020092100A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
CN115697307A (zh) * 2020-06-19 2023-02-03 葛兰素史密斯克莱知识产权(第2 号)有限公司 包含达普司他的制剂
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
US11827614B2 (en) 2021-05-21 2023-11-28 Merck Sharp & Dohme Llc Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
US20240327929A1 (en) * 2021-08-12 2024-10-03 Merck Sharp & Dohme Llc Dosage regimen for administration of belzutifan
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds
AU2023407370A1 (en) * 2022-12-22 2025-07-03 Cogent Biosciences, Inc. Bezuclastinib formulations
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
KR102824931B1 (ko) * 2023-10-17 2025-07-08 주식회사 참인티그레이션 오일 유화 공법을 이용하여 제조되는 반려동물 건강 영양제 및 이의 제조방법
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
DE60038624T2 (de) 1999-10-07 2009-06-10 Aquilar-Cordova, Carlos, Estuardo, Newton Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
US7115265B1 (en) 2001-05-14 2006-10-03 Duke University Four genetic tumor markers specific for human glioblastoma
CN101827585A (zh) 2007-10-19 2010-09-08 雅培股份有限两合公司 含有n-芳基脲基化合物的固态分散体产品
US8691866B2 (en) * 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈(enzalutamide)之調和物
CN105307636A (zh) 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备
EP3417851B1 (en) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
CN113209024A (zh) 2013-12-31 2021-08-06 阿森迪亚制药有限责任公司 疏水性化合物的药物组合物
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma

Similar Documents

Publication Publication Date Title
Berl et al. Oral tolvaptan is safe and effective in chronic hyponatremia
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法(ベムラフェニブ及びmdm2阻害剤)
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
KR102319078B1 (ko) 궤양성 대장염의 치료용 의약 조성물
JP2019516711A5 (cg-RX-API-DMAC7.html)
JP2005525345A5 (cg-RX-API-DMAC7.html)
EP2575783B1 (en) Methods and compositions for oral pharmaceutical therapy
JP2020514292A5 (cg-RX-API-DMAC7.html)
JP2019515908A5 (cg-RX-API-DMAC7.html)
JP2019514965A5 (cg-RX-API-DMAC7.html)
JP2016529285A5 (cg-RX-API-DMAC7.html)
JP2024516795A (ja) エベロリムスおよびアムセネストラントを含む組合せ物
JP2016530238A5 (cg-RX-API-DMAC7.html)
JP2017511377A5 (cg-RX-API-DMAC7.html)
JP2021535147A5 (cg-RX-API-DMAC7.html)
JP2024502446A5 (cg-RX-API-DMAC7.html)
JP2006518731A5 (cg-RX-API-DMAC7.html)
IL292770A (en) Formulations and dosages of polyethylene glycol-modified oricase
EA032067B1 (ru) Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита
US11083722B2 (en) Combination therapies for the treatment of breast cancer
US20250319084A1 (en) Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
JP2020523317A5 (cg-RX-API-DMAC7.html)
US20170224670A1 (en) Drug Combination to Treat Melanoma
JP2020515523A5 (cg-RX-API-DMAC7.html)
JP2021503448A5 (cg-RX-API-DMAC7.html)